

6. Literatur

- Ahlers O, Hildebrandt B, Dieing A, et al. Stress induced changes in lymphocyte subpopulations and associated cytokines during whole body hyperthermia of 41,8 to 42,2 degrees C. Eur J Appl Physiol 2005; 95 (4): 298-306
- Al- Awami M, Schillinger M, Geschwandtner ME, et al. Low level laser treatment of primary and secondary Raynaud´s phenomenon. Vasa 2001; 30: 281-4
- Applegate LA, Scaletta C, Panizzon R, et al. Induction of the putative protective protein ferritin by infrared radiation: Implications in skin repair. Int J Mol Med 2000; 5 (3): 247-51
- Ardenne M v., Kirsch R. On the methodology of extreme hyperthermia, with special reference to multi- step cancer chemotherapy. Dtsch Gesundheitsw 1965; 20 (43): 1935-40
- Ardenne M v. Principles and 1977 concept of cancer- multistep therapy. Physiological fundamentals of the new timing. Selectotherm local hyperthermia. Arch Geschwulstforsch 1978; 48 (6): 504-20
- Ardenne A v. IRATHERM 1000- Bedienungsanleitung und technische Beschreibung. Von Ardenne Institut für Angewandte Medizinische Forschung GmbH. 1999: 2
- Atanackovic D, Pollok K, Faltz C, et al. Patients with solid tumors treated with high-temperature whole- body- hyperthermia (WBH) show a redistribution of naive/memory T cells subtypes. Am J Physiol Regul Integr Comp Physiol 2005 Oct 27; Epub ahead of print
- Bachem A. Lichtdurchdringung der menschlichen Haut. Strahlentherapie 1931; 39: 30-56
- Bathacharyya S, Ghosh AK, Pannu J, et al. Fibroblast expression of the coactivator p 300 governs the intensity of profibrotic response to transforming growth factor beta. Arthritis Rheum 2005; 52 (4): 1248-58
- Baumhoer D, Steinbrück I, Götz W. Haut und Hautanhangsgebilde. In: Baumhoer (Hrsg.): Histologie mit Schemazeichnungen. 1. Auflage, Urban und Fischer, München, Jena, 2000: 226-7
- Bäuml H, Scherf HP, Aurisch R, et al. Einfluß einer Serie von Infrarot- A- Ganzkörperbestrahlungen auf die Fließeigenschaften des Blutes und die Hämodynamik. Perfusion 1990; 4: 137-43

- Becker H, Franz O, Hinckel P, et al. Chronic heat stress modulates the immune system in the preclinical phase of murine lupus erythematosus. *Immun Infekt* 1993; 21 (1): 23-4
- Belch JJF. Raynaud's phenomenon: its relevance to scleroderma. *Ann Rheum Dis* 1991; 50: 839-45
- Bierbrauer A v., Schilk I, Lucke C, et al. Infrared- thermography in the diagnosis of Raynaud's phenomenon in vibration- induced white finger. *Vasa* 1998; 27: 94-9
- Black CM, Halkier- Sorensen L, Belch JJ, et al. Oral iloprost in Raynaud's phenomenon secondary to systemic sclerosis: a multicentre, placebo- controlled, dose- comparison study. *Br J Rheumatol* 1998; 37: 952-60
- Brown KM, Middaugh SJ, Haythornthwaite JA, et al. The effects of stress, anxiety and outdoor temperature on the frequency and severity of Raynaud's attacks: the Raynaud's Treatment Study. *J Behav Med* 2001; 24 (2): 137-53
- Bunker CB, Terenghi G, Springall DR, et al. Deficiency of calcitonin gene- related peptide in Raynaud's phenomenon. *Lancet* 1990; 336 (8730): 1530-3
- Calguneri M, Apras S, Ozbalkan Z, et al. The efficacy of oral cyclophosphamide plus prednisolone in early diffuse systemic sclerosis. *Clin Rheumatol* 2003; 22 (4-5): 289-94
- Casale R, Generini S, Luppi F, et al. Pulse cyclophosphamide decreases sympathetic postganglionic activity, controls alveolitis and normalizes vascular tone dysfunction (Raynaud's phenomenon) in a case of early systemic sclerosis. *Arthritis Rheum* 2004; 51: 665-9
- Chua C, Diglio C, Siu B, et al. Angiotensin II induces TGF- β 1 production in rat heart endothelial cells. *Biochem. Biophys. Acta* 1994; 1223: 141-7
- Clark S, Dunn G, Moore T, et al. Comparison of thermography and laser doppler imaging in the assessment of Raynaud's phenomenon. *Microvasc Res* 2003; 66 (1): 73-6
- Clements PJ, Lachenbruch PA, Seibold JR, et al. Skin thickness score in systemic sclerosis: an assessment of interobserver variability in 3 independent studies. *J Rheumatol* 1993; 20 (11): 1892-6
- Collins KJ, Few JD, Forward TJ, et al. Stimulation of adrenal glucocorticoid secretion in man by raising the body temperature. *J Physiol* 1969; 202 (3): 645-60

- Comparison of sustained- release nifedipine and temperature bio- feedback for treatment of primary Raynaud´s phenomenon: results from a randomized clinical trial with 1- year follow- up. *Arch Intern Med* 2000; 160: 1101-8
- Crawford DC, Chobanian AV, Brecher P. Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. *Circ Res* 1994; 74: 727-39
- Cutolo M, Pizzorni C, Tuccio M, et al. Nailfold videocapillaroscopic patterns and serum autoantibodies in systemic sclerosis. *Rheumatology (Oxford)*; 43 (6): 719-26
- Dauterstedt W, Hecht HC, Mayer WK, et al. IRA- Therm- eine neuartige Infrarot- A- Hyperthermieeinrichtung. *Z klin Med* 1987; 42: 953-7
- Denton CP, Bruce TD, Dorado MB, et al. Probuocol improves symptoms and reduces lipoprotein oxidation susceptibility in patients with Raynaud´s phenomenon. *Rheumatology* 1999; 38: 309-15
- Distler O, Distler JH, Scheid A, et al. Uncontrolled expression of vascular endothelial growth factor and its receptors leads to insufficient skin angiogenesis in patients with systemic sclerosis. *Circ Res* 2004; 95 (1): 109-16
- Dziadzio M, Denton CP, Smith R, et al. Losartan therapy for Raynaud´s phenomenon and scleroderma: clinical and biochemical findings in a fifteen- week, randomized, parallel- group, controlled trial. *Arthritis Rheum* 1999; 42: 2646-55
- Edwards JM, Phinney ES, Taylor LM jr., et al. Alpha 2- adrenergic receptor levels in obstructive and spastic Raynaud´s syndrome. *J vasc Surg* 1987; 5 (1): 38-45
- Gore J, Silver R. Oral sildenafil for the treatment of Raynaud´s phenomenon and digital ulcers secondary to systemic sclerosis. *Ann Rheum Dis* 2005; 64 (9): 1387
- Grassi W, De Angelis R, Lapadula G, et al. Clinical diagnosis found in patients with Raynaud´s phenomenon: a multicentre study. *Rheumatol Int* 1998; 18: 17-20
- Harvey GR, Butts S, Rands AL, et al. Clinical associations with anti- RNA- polymerase antibodies in systemic sclerosis. *Clin Exp Immunol* 1999; 117: 395-402
- Heckel M. Ganzkörperhyperthermie und Fiebertherapie. *Grundlagen und Praxis*. Hippokrates Verlag, Stuttgart, 1990
- Herrick AL. Pathogenesis of Raynaud´s phenomenon. *Rheumatology (Oxford)* 2005; 44 (5):587-96
- Hershler C, Conine TA, Nunn A. Assessment of an infra-red non- contact sensor for routine skin temperature monitoring: a preliminary study. *J Med Eng Technol* 1992; 16 (3): 117-22

- Hirschl M, Katzenschlager R, Ammer K, et al. Double- blind, randomized, placebo controlled low level laser therapy study in patients with primary Raynaud's phenomenon. *Vasa* 2002; 31: 91-4
- Hochmuth O, Schreiner M, Schuster F. Ein neues Messgerät für die Dermatologie. *Humboldt Spektrum* 1996; 1: 44-6
- Izumi A, Koga S, Maeta M. Effects of in vitro hyperthermia on murine and human lymphocytes. *Cancer* 1983; 51 (11): 2061-5
- Jager H, Grafenstein K, Petzold M, et al. Use of computer assisted Doppler-sonography and rheography in acral vascular diagnosis in progressive systemic sclerosis. *Z Gesamte Inn Med* 1990; 15 (10):287-9
- Ju H, Zhao S, Jassal D, et al. Effect of AT- 1 receptor blockade on cardiac collagen remodelling after myocardial infarction. *Cardiovasc Res* 1997; 35: 223-32
- Kahaleh MB. Raynaud's phenomenon and the vascular disease in scleroderma. *Curs Opin Rheumatol* 2004; 16 (6) 718-22
- Kanetaka T, Komiyama T, Onozuka A, et al. Laser Doppler skin perfusion pressure in the assessment of Raynaud's phenomenon. *Eur J Vasc Endovasc Surg* 2004 ; 27 : 414-6
- Kingma K, Wollersheim H, Thien T. Double- blind, placebo- controlled study of intravenous prostacyclin on hemodynamics in severe Raynaud's phenomenon: the acute vasodilatory effect is not sustained. *J Cardiovasc Pharmacol* 1995; 26: 388-93
- Krieg T, Perlish JS, Mauch C, et al. Collagen synthesis by scleroderma fibroblasts. *Ann NY Acad Sci* 1985; 460: 375-86
- Lindberg LG, Tamura T, Oberg PA. Photoplethysmography Part I: Comparison with laser Doppler flowmetrie. *Med Biol Eng Comput* 1991 a; 29 (1): 40-7
- Lindberg LG, Tamura T, Oberg PA. Photoplethysmography Part II: Comparison with laser Doppler flowmetrie. *Med Biol Eng Comput* 1991 b; 29 (1): 48-54
- Le Roy EC, Black CM, Fleischmajer R. Scleroderma. Classification, subset and pathogenesis. *J Rheumatol* 1988; 15: 202-05
- Le Roy EC. Systemic sclerosis : a vascular perspective. *Rheum Dis Clin North Am* 1996; 22: 675-94
- Manzella JP, Roberts NJ. Human macrophage and lymphocyte responses to mitogen stimulation after exposure to influenza virus, ascorbic acid and hyperthermia. *J Immunol* 1979; 123 (5): 1940-4

- Masi AT, Rodnan GP, Medsger TA, et al. Preliminary criteria for the classification of systemic sclerosis (scleroderma). *Arthritis Rheum* 1980; 23: 581-90
- Matsukawa Y, Saito O, Aoki M, et al. Long- term administration of beraprost, an oral prostacyclin analogue , improves pulmonary diffusion capacity in patients with systemic sclerosis. *Prostaglandins Leukot. Essent Fatty Acids* 2002; 67 (1): 45-9
- McGaha TL, Le M, Kodera T, et al. Molecular mechanisms of interleukin- 4 induced up- regulation of type I- collagen gene expression in murine fibroblasts. *Arthritis Rheum* 2003; 48 (8): 2275-84
- Meffert H, Sönnichsen N, Meffert B. Skin rewarming curves. *Lancet* 1972; 7780 (2): 679-70
- Meffert H, Hecht HC, Günther H, et al. Biophysikalische Ergebnisse des klinischen Tests der IRA- Therm- Hyperthermieeinrichtung der 2. Generation. *ThermoMed* 1990 a; 6: 71-78
- Meffert H, Buchholtz I, Brenke A. Milde Infrarot- A- Hyperthermie zur Behandlung der systemischen Sklerodermie. *Dermatol Monatsschr* 1990 b; 176 (11): 683-6
- Meffert H, Scherf HP. Nichtmedikamentöse Behandlung der arteriellen Hypertonie. *Therapeutikon (Karlsru.)* 1991; 5: 440-5
- Meffert H, Scherf HP, Meffert B, et al. Auswirkungen von Serienbestrahlungen mit wassergefilterter Infrarotstrahlung auf Gesunde und Kranke mit arterieller Hypertonie b.z.w. systemischer Sklerodermie. *Intern Saunaarchiv* 1992; 9: 149-58
- Meffert H, Scherf HP, Meffert B. Milde Infrarot- A- Hyperthermie zur Behandlung von Erkrankungen des rheumatischen Formenkreises- Anhaltende Verminderung der Aktivität polymorphkerniger Granulozyten. *Intern Saunaarchiv* 1993; 4: 125-31
- Meffert B, Meffert H. Optical radiation and its effect on the skin. *Biomed Tech* 2000; 45 (4): 98-104
- Merkel PA, Herlyn K, Martin RW, et al. Measuring disease activity and functional status in patients with scleroderma and Raynaud´s phenomenon. *Arthritis Rheum* 2002; 46 (9): 2410-20
- Murrell GCA, Francis MJO, Bromley L. Modulation of fibroblast proliferation by oxygen free radicals. *Biochem J* 1990; 265: 659-65
- Okada A, Inaba R, Furuno T, et al. Usefulness of blood parameters, especially viscosity, for the diagnosis and elucidation of pathogenic mechanisms of the hand- arm vibration syndrome. *Scand J Work Environ Health* 1987; 13 (4): 358-62

- Okano Y. Antinuclear antibody in systemic sclerosis (scleroderma). *Rheum Dis Clin North Am* 1996; 22: 709-35
- O'Reilly D, Taylor L, el- Hadidy K, et al. Measurement of cold challenge responses in primary Raynaud's phenomenon and Raynaud's phenomenon associated with systemic sclerosis. *Ann Rheum Dis* 1992; 51: 1193-6
- Owens GR, Follansbee WP. Cardiopulmonary manifestations of systemic sclerosis. *Chest* 1987; 91: 118-27
- Parkin A, Wilkinson D, Smye SW, et al. The clinical application of forearm and hand blood flow measurements using a gamma camera. *Surgery* 1989; 106 (1):26-32
- Pearson JD. The Endothelium: its role in Scleroderma. *Ann Rheum Dis* 1991; 50: 866-71
- Pistorius MA, Planchon B, de Faucal P. Plethysmographic cold test for diagnosis and elevation of the severity of Raynaud's phenomenon. Validation of the method by factorial analysis of correspondences in 541 patients. *Int Angiol* 1994; 13: 10-4
- Planchon B, Pistorius MA, Beurrier D, et al. Primary Raynaud's phenomenon. Age of onset and pathogenesis in a prospective study of 424 patients. *Angiology* 1994; 45 (8): 677-86
- Ponte E, Catagna D, Cattinelli S. Computerized digital thermometry in Raynaud's disease. Personal experience. *Minerva Med* 1998; 89 (7-8): 259-66
- Preliminary criteria for the classification of systemic sclerosis (scleroderma). Subcommittee for scleroderma criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. *Arthritis Rheum* 1980; 23 (5): 581-90
- Prevoo ML, van't Hof MA, Kuper HH, et al. Modified disease activity scores that include twenty- eight- joint counts. Development and validation in a prospective longitudinal study of patients with rheumatoid arthritis. *Arthritis Rheum* 1995; 38 (1): 44-8
- Raynaud M. On local asphyxia and symmetrical gangraene of the extremities. *The New Sydenham Society* 1864: 1888
- Renz- Polster H, Krautzig S, Braun J. Sklerodermie. In: *Basislehrbuch Innere Medizin*. Renz- Polster, Krautzig, Braun (Hrsg.). 3. Auflage, Urban und Fischer, München, Jena 2004: 1036-7

- Rhind SG, Gannon GA, Shepard RJ, et al. Cytokine induction during exertional hyperthermia abolished by core temperature clamping: neuroendocrine regulatory mechanisms. *Int J Hyperthermia* 2004; 19 (3): 153-8
- Rietschel L, Meffert H, Sönnichsen N. Measurement of skin temperature with the infrared radiation measuring device by Kortum. *Dermatol Monatsschr* 1969; 155: 802-12
- Roberts NJ, Steigbigel RT. Hyperthermia and human leukocyte functions: effects on response of lymphocytes to mitogen and antigen and bactericidal capacity of monocytes and neutrophils. *Infect Immun* 1977; 18 (3): 673-9
- Rodnan GP, Myerowitz RL, Justh GO. Morphologic changes in the digital arteries of patients with progressive systemic sclerosis (scleroderma) and Raynaud's phenomenon. *Medicine (Baltimore)* 1980; 59: 393-408
- Rosenkranz S, Diet F, Karasch T, et al. Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud's phenomenon. *Ann Intern Med* 2003; 139 (10):871-3
- Rzeznik J. Eine neue Technik zur loko- regionalen Wärmetherapie mit wassergefilterter Infrarot- A- Strahlung. In: Vaupel, Krüger (Hrsg.): Wärmetherapie mit wassergefilterter Infrarot- A- Strahlung. Hippokrates, Stuttgart 1992: 23-37
- Saito E, Fujimoto M, Hasegawa M, et al. CD19- dependent B- lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight- skin mouse. *J Clin Invest* 2002; 109 (11): 1453-62
- Sakkas LI. New developments in the pathogenesis of systemic sclerosis. *Autoimmunity* 2005; 38 (2) 113-6
- Salerni R, Rodnan GP, Leon DF, et al. Pulmonary hypertension in the CREST- syndrome variant of progressive systemic sclerosis (scleroderma). *Ann Intern Med* 1977; 86: 394-9
- Sambo P, Amico D, Giacomelli R, et al. Intravenous N- acetylcysteine for treatment of Raynaud's phenomenon secondary to systemic sclerosis: a pilot study. *J Rheumatol* 2001; 28: 2257-62
- Scherf HP, Meffert H, Bäuml K, et al. Wirkung einer einmaligen Infrarot- A- Hyperthermie auf Körpertemperatur, Herzfrequenz, Blutdruck und Blutviskosität bei Gesunden und Patienten mit arterieller Hypertonie der Stadien I und II. *Dermatol Monatsschr* 1989; 175: 733-40

- Schmidt KL. Hyperthermie und Fieber. Wirkungen bei Mensch und Tier. 2. Auflage, Hippokrates Verlag, Stuttgart, 1987
- Schmidt KL. Effects of whole body hyperthermia on inflammations and immune reactions: experimental aspects. *Phys Med Rehab Kuror* 2004; 14: 227-35
- Schuhfried O, Vacariu G, Lang T, et al. Thermographic parameters in the diagnosis of secondary Raynaud's phenomenon. *Arch Phys Med Rehabil* 2000; 81:495-9
- Seibold JR, Korn JH, Simms R, et al. Recombinant human relaxin in the treatment of scleroderma. A randomized, double-blind, placebo-controlled trial. *Ann Intern Med* 2000; 132 (11): 871-9
- Seibold JR. Scleroderma. In: Ruddy, Harris jr. and Sledge (Hrsg.): *Kelley's Textbook of Rheumatology*, 6. Auflage, W.B. Sanders Company, Philadelphia, 2001: 1211-39
- Siewert HD, Strangfeld D, Scherf HP. Untersuchungen zur Hämodynamik bei Patienten mit arterieller Hypertonie unter milder Infrarot- A- Hyperthermie (IRA-Therm II). *Dermatol Monatsschr* 1989; 175: 741-46
- Smyth AE, Bell AL, Bruce IN, et al. Digital vascular responses and serum endothelin- 1 concentrations in primary and secondary Raynaud's phenomenon. *Ann Rheum Dis* 2000; 59:870-4
- Spencer- Green G. Outcomes in primary Raynaud's phenomenon: a meta-analysis of the frequency, rates and predictors of transition to secondary diseases. *Arch Intern Med* 1998; 158 (6): 595-600
- Steen VD, Medsger TA jr. The value of the Health Assessment Questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis over time. *Arthritis Rheum* 1997; 40 (11): 1984-91
- Stein CM, Tanner SB, Awad JA, et al. Evidence of free-radical-mediated injury (isoprostane overproduction) in scleroderma. *Arthritis Rheum* 1996; 39: 1146-50
- Steiner M, Wenzel A. Entwicklung der Hard- und Software zur Einführung der akralen Wiedererwärmung in die klinische Praxis. Diplomarbeit im Fachbereich Elektrotechnik der Humboldt- Universität zu Berlin 1992
- Steinhausen D, Mayer WK, Ardenne M v. Evaluation of systemic tolerance of 42,0 degrees C infrared- A- whole body hyperthermia in combination with hyperglycemia and hyperoxemia. A phase- I- study. *Strahlenther Onkol* 1994; 170 (6): 322-34
- Thompson AE, Shea B, Welch V, et al. Calcium-channel blockers for Raynaud's phenomenon in systemic sclerosis. *Arthritis Rheum* 2001; 44 (8): 1841-7

- Thulesius O. Primary and Secondary Raynaud- Phenomenon. Acta Chir Scand Suppl 1976; 465: 5-6
- Tsuji- Yamada J, Nakazawa M, Minami M, et al. Increased frequency of interleukin-4 producing CD 4+ and CD 8+ cells in peripheral blood from patients with systemic sclerosis. J Rheumatol 2001; 28 (6): 1252-8
- Turton EP, Kent PJ, Kester RC. The aetiology of Raynaud's phenomenon. Cardiovasc Surg 1998; 6 (5): 431-40
- Valentini G. The assessment of the patient with systemic sclerosis. Autoimmun Rev 2003; 2 (6): 370-6
- Vayssairat M. Controlled multicentre double blind trial of an oral analog of prostacyclin in the treatment of primary Raynaud's phenomenon. French Microcirculation Society Multicentre Group for the study of Vascular Acrosyndromes. J Rheumatol 1996; 23: 1917-20
- Watson HR, Robb R, Belcher G. Seasonal variation of Raynaud's phenomenon secondary to systemic sclerosis. J Rheumatol 1999; 26: 1734-7
- Weiner ES, Earnshaw WC, Senecal JL. Clinical association of anticentromere antibodies and antibodies to topoisomerase I. Arthritis Rheum 1988; 31: 378-85
- Weller E, Ullrich D. Infrarot- A- Anwendungen bei Patienten mit Analgetika- Abusus wegen chronischer Rückenschmerzen. 95. Kongreß der Gesellschaft für Physikalische Medizin und Rehabilitation am 05.10.1990 in Chemnitz
- Wigley FM, Wise RA, Seibold JR, et al. Intravenous iloprost infusion in patients with Raynaud's phenomenon secondary to systemic sclerosis. A multicentre, placebo-controlled, double- blind study. Ann Intern Med 1994; 120: 199-206
- Wise RA, Wigley FM, White B, et al. Efficacy and tolerability of a selective alpha(2C)- adrenergic receptor blocker in recovery from cold- induced vasospasm in scleroderma patients: a single- centre, double- blind, placebo- controlled, randomized crossover study. Arthritis Rheum 2004; 50: 3994-4001
- Yamamoto T, Sawada Y, Katayama I, et al. Nodular scleroderma: increased expression of connective tissue growth factor. Dermatology 2005; 211 (3): 218-23